Glow turned ALL the way up
The global market for glucagon-like peptide 1 (GLP-1) agonists segmented by product (condition/brand) [type 2 diabetes [Byetta (exenatide), Victoza (liraglutide), Bydureon BCise (exenatide), Trulicity (dulaglutide), Soliqua (lixisenatide/insulin glargine) FDC, Xultophy / iDegLira (liraglutide / insulin degludec) FDC, Ozempic (semaglutide), Rybelsus (semaglutide), Mounjaro (tirzepatide)], obesity & weight loss management [Saxenda (liraglutide), Wegovy (semaglutide), Zepbound (tirzepatide)]], route of administration (subcutaneous, oral), pipeline analysis, and geography
doi: 10.3389/fendo.2019.00888 78 Barreiro ArcosML
Ramos-Tovar E, Muriel P (2020) Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage